License out

Out-Licensing Opportunities at Hartington Pharmaceuticals, S.L

Our goal is to provide patients with high-quality product in the shortest time possible. Out-licensing reduces our time-to-market, ensuring that the therapies of the future reach those who need them most. The following out-licensing opportunities are currently available:

Product: Nasodren® - Medical Device Class I
Indication:

  • Acute or chronic recurrent inflammation of the para nasal sinuses (rhinosinusitis): catarrhal or purulent maxillary rhinosinusitis, frontitis, ethmoiditis, sphenoiditis, or combined rhinosinusitis.
  • Acute purulent rhinosinusitis, accompanied by generalized infection or orbital complications.
  • In case of orbital complications or generalized infection, NASODREN® should be administered in combination with antibiotics.
  • Acute exudative or purulent otitis media, chronic exudative, acute secretory otitis media or purulent otitis media. In case of fever, Nasodren® should be administered in combination with antibiotics.
  • In postoperative care, after nasal or nasosinusal surgery.

If you want more information, you can download the non-confidential presentation for this product (this document is password protected).

For more details please contact us:

All enquiries should be directed to Ms. Nathalie Bofarull or Mr. Thomas Riesterer

Hartington Pharmaceutical, S.L.
calle Marina, 16-18, planta 30C
08005, Barcelona, Spain
Tel +34(93)221-23-71
Fax +34(93)221-92-09
e-mail: info@hartington.org

Hartington Pharma owns Nasodren® for sinusitis treatment